logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The pharmaceutical industry reaffirms its commitment to R&D in rare diseases

The number of new treatments available against rare pathologies has multiplied by 20 in Europe since 2000
The industry insists on collaboration with governments and health systems to facilitate patients’ access to medicines

Pharmaindustry joins the new phase of the European initiative #WeWontRest, focused on rare diseases

Source: www.farmaindustria.es

“We will not rest until treatments for rare diseases are not uncommon.” This is one of the main messages of the new phase of the European information initiative #WeWontRest, which this time has as main objective to raise awareness in society about the importance of continuing to work in the research and development of new therapies for patients suffering infrequent pathologies and explain the commitment that the pharmaceutical industry has for this purpose.

As in the previous stages of #WeWontRest, which started two and a half years ago in order to reach society about the pharmaceutical industry’s commitment to research and people’s health, Farmaindustria has joined this phase of the campaign through their social media profiles. In this case, it should be noted that, although very significant progress has been made since 2000, the challenge ahead is still very demanding.

The general director of the European Federation of the Pharmaceutical Industry (Efpia), Nathalie Moll, has underlined the commitment of pharmaceutical companies in Europe to the investigation of new remedies against these pathologies, as evidenced by the fact that only between 2000 and 2016 The number of clinical trials against these ailments has grown by 88%.

In the case of Spain, “the commitment of the pharmaceutical industry for the research and development of treatments for infrequent diseases is indisputable and, as the data shows, growing”, explains the deputy director general of Farmaindustria, Javier Urzay, who emphasizes “the international reference position that our country plays in clinical research ”. Thus, one in six clinical trials promoted in Spain by pharmaceutical companies already corresponds to drugs designated as orphans. These are figures obtained from the database of the BEST Project for the promotion of biomedical R&D promoted by Farmaindustria, which monitors the research activity of 50 pharmaceutical companies, four cooperative research groups and 54 hospitals in the country.

As a result of these efforts of the innovative pharmaceutical sector, from the year 2000 to 2018, 164 new treatments have been approved in Europe against almost a hundred rare diseases, while before 2000 there were only eight treatments available against these pathologies, which in their together they affect 30 million people in Europe (one in 17), half of them children. A key factor in this progress was the approval, in 2000, of the European Orphan Medicines Regulation, which established incentives for its research, development and commercialization.

Despite these advances, it is estimated that only 5% of rare diseases have an approved treatment, which shows that there is still much work to be done, given, on the one hand, the low prevalence of these diseases, and, on the other, the fact that its approach is very complex from the scientific point of view. For all these reasons, Moll defends the need for “a stable and predictable regulatory framework that allows us to continue supporting and inspiring new research”.

Promote access
But it is of little use to research and develop new medications against infrequent diseases if patients then have difficulty accessing new treatments. “Once a new drug is approved in Europe, industry, healthcare systems and governments have a shared responsibility to ensure that patients will have access to it,” says Moll, who understands that all parties have to work in a way joint to make such access as quick as possible, for example, through “flexible financing formulas”, as is already being considered in different European countries.

In the specific case of the new gene or cell-based therapies that have curative capacity and that come to replace traditional treatments that were extended throughout the patient’s life, Efpia insists that governments, health systems and The industry itself must continue to cooperate to find new ways to reconcile patients’ access to new treatments with the sustainability of the health system.

In Distefar we add to the importance of focusing efforts in the study of the treatments of infrequent diseases that affect so many people.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.